Die Hersteller des Medikaments, die Pharmaunternehmen Eisai (Japan) und Biogen (USA), hatten daraufhin eine zweite Prüfung beantragt. Die EMA-Experten kamen dann im November zu dem Schluss ...
Die Hersteller des Medikaments, die Pharmaunternehmen Eisai (Japan) und Biogen (USA), hatten daraufhin eine zweite Prüfung beantragt. Die EMA-Experten kamen daraufhin im November zu dem Schluss, dass ...
TecDax 3.800 10:53:45-0,57% 10:53:45 ...
Biogen Inc Aktie und aktueller Aktienkurs: Bleiben Sie über den aktuellen Aktienkurs von Biogen Inc (BIIB) stets informiert - direkt auf dieser Seite. Behalten Sie den vor- und nachbörslichen ...
ZUG, Switzerland and BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...
Headquartered in Zug, Switzerland, CRISPR Therapeutics AG (NASDAQ:CRSP) develops transformative gene-based medicines for serious diseases through its proprietary CRISPR/Cas9 platform. The CRISPR ...
Stoke Therapeutics Inc. and Biogen Inc. said Tuesday they are entering a collaboration to develop and commercialize a treatment for Dravet syndrome, a severe form of epilepsy that starts in childhood.
Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology ...
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback